دورية أكاديمية
Fluorometric determination of hydroflumethiazide in human plasma and urine after its oral administration.
| العنوان: | Fluorometric determination of hydroflumethiazide in human plasma and urine after its oral administration. |
|---|---|
| المؤلفون: | Brors O, Jacobsen S, Arnesen E |
| المصدر: | European journal of clinical pharmacology [Eur J Clin Pharmacol] 1977 Jan 03; Vol. 11 (2), pp. 149-54. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print Cited Medium: Print ISSN: 0031-6970 (Print) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin, New York, Springer. |
| مواضيع طبية MeSH: | Hydroflumethiazide/*analysis, Administration, Oral ; Adult ; Aged ; Body Weight ; Female ; Half-Life ; Humans ; Hydroflumethiazide/blood ; Hydroflumethiazide/urine ; Male ; Methods ; Middle Aged ; Spectrometry, Fluorescence |
| مستخلص: | A spectrofluorometric method for determination of hydroflumethiazide in human plasma and urine has been developed. The limit of detection was 10 ng/ml plasma and 100 ng/ml urine. The plasma concentration of hydroflumethiazide was determined for 9-11 hours and excretion in urine for 24-37 hrs after oral administration of about 1 mg/kg body weight to 7 subjects. Plasma half life in healthy subjects was 1.9-2.1 h, and 2.7-8.6 h in patients during the period 4-9 hrs after dosing. Cumulative excretion in urine was 67-79% of the dose during 31-37 hrs in 6 subjects; one patient with renal disease was found to excrete only 25.8% of dose during 24 hours. Renal clearance of hydroflumethiazide was higher in the healthy subjects (0.29-0.44 1 h-1 kg-1) than in the patients (0.040-0.15 1 h-1 kg-1). Plasma half life of hydroflumethiazide was not closely correlated with renal clearance of the drug, which suggests that other factors may play a role in determining plasma half life. |
| References: | Curr Ther Res Clin Exp. 1964 Nov;6:670-6. (PMID: 14240757) Lancet. 1959 Sep 12;2(7098):311-3. (PMID: 13801214) Curr Ther Res Clin Exp. 1961 Sep;3:365-77. (PMID: 13775251) Dtsch Med Wochenschr. 1965 Oct 22;90(43):1905-8. (PMID: 5831641) Lancet. 1959 Nov 7;2(7106):765-8. (PMID: 13846620) JAMA. 1963 Aug 24;185:640-2. (PMID: 13955916) AMA Arch Intern Med. 1957 Oct;100(4):582-96. (PMID: 13457483) Curr Ther Res Clin Exp. 1961 Jul;3:320-8. (PMID: 13700729) Postgrad Med J. 1971 Oct;47(552):639-43. (PMID: 5158836) Am Heart J. 1969 Jul;78(1):16-21. (PMID: 5794789) Dtsch Med Wochenschr. 1964 Jun 5;89:1101-4. (PMID: 14152365) Ugeskr Laeger. 1972 May 15;134(20):1043-7. (PMID: 5064948) J Pharm Sci. 1974 Nov;63(11):1793-5. (PMID: 4427251) N Engl J Med. 1962 Sep 13;267:541-3. (PMID: 14495300) Lancet. 1958 Jun 7;1(7032):1195-9. (PMID: 13550966) J Pharm Sci. 1975 Aug;64(8):1309-12. (PMID: 1151702) |
| المشرفين على المادة: | 501CFL162R (Hydroflumethiazide) |
| تواريخ الأحداث: | Date Created: 19770103 Date Completed: 19770425 Latest Revision: 20190813 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/BF00562907 |
| PMID: | 837968 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 0031-6970 |
|---|---|
| DOI: | 10.1007/BF00562907 |